59% — When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List
Leader: Before 2027 at 59% · Kalshi 59% · 4 contracts · $400 volume · medium confidence
Updated 2026-06-29 02:44:23 UTC

Tracks the leading outcome in a winner-take-all prediction market set with 4 outcomes.

Why this matters:
This prediction estimates a 43% chance that the FDA will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by a specific future date. The current probability reflects BPC-157's status as a peptide without FDA approval for therapeutic use, balanced against growing research interest and potential pathway movements. Key factors driving this level include the peptide's current regulatory classification, the pace of clinical research submissions, and FDA's historical approach to bulk drug categorization. The most significant catalyst would be an FDA announcement, formal petition for reclassification, or a major clinical program submission that signals regulatory acceptance. BPC-157's track record in research demonstrates bioactivity in animal models, but human clinical evidence remains limited, creating uncertainty about whether the FDA would elevate its classification status in the near term.

Key factors:
- Current BPC-157 regulatory status as an unapproved investigational substance without existing Category 1 designation
- Pace of clinical trial initiation or IND applications submitted to FDA that specifically reference BPC-157
- Historical FDA timelines for bulk drug substance reclassifications and typical catalyst events that trigger such reviews
- Competition from other peptide therapies with more advanced clinical development status
- Public or regulatory signals indicating FDA's receptiveness to BPC-157 programs in therapeutic areas like gastroenterology or neuroprotection

Contracts:
- When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List?: Before 2027 — 59¢ Kalshi $0 (weight 0%)
- When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List?: Before September — 51¢ Kalshi $193 (weight 48%)
- When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List?: Before November — 49¢ Kalshi $107 (weight 27%)
- When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List?: Before July — 3¢ Kalshi $100 (weight 25%)

---

## Methodology

SimpleFunctions aggregates live YES-side prices from Kalshi and Polymarket contracts bound to this question. For binary topics the headline is the liquidity-weighted mid-price (weight = log(1 + 24h volume) × freshness, where freshness is 1.0 if updated <24h, 0.7 if <7d, 0.4 otherwise). For multi-outcome (winner-take-all) topics the headline is the current leader's price — disjoint outcomes are never arithmetically averaged. Snapshots refresh every 5 minutes during market hours.

## SF Signal

- SF Index, regime, and 30d Brier calibration are computed separately and surfaced at https://simplefunctions.dev/admin/calibration.
- No SimpleFunctions index / regime / calibration signal is bound to this topic yet — the headline above is market-derived only.

---

*Last verified: 2026-06-29T02:20:49.492Z*

By SimpleFunctions — https://simplefunctions.dev/

Cite as: "59% per prediction markets (SimpleFunctions, June 2026)"
Canonical: https://simplefunctions.dev/answer/fdaannounce-bpc
Full data: https://simplefunctions.dev/api/public/query?q=When%20will%20FDA%20announce%20Reclassification%20of%20BPC-157%20to%20Category%201%20of%20the%20Bulk%20Drug%20Substances%20List
Provider: SimpleFunctions — https://simplefunctions.dev